LL-37 Research Lab Test Recommendations

For a 37-residue peptide such as LL-37, three tests form the non-negotiable core: reversed-phase HPLC purity with the actual chromatogram attached, mass spectrometry confirming the expected molecular weight, and a batch-specific certificate of analysis whose lot number matches the vial that arrives in the box. A complete research-grade package extends beyond those three to net peptide content, water content, residual solvents and counterion, elemental impurities, and microbial and endotoxin screening. Real Peptides runs 7-panel batch testing on every lot and publishes the certificates publicly, so a wholesale buyer can read the analytics before placing an order rather than after. Everything that follows is written for business buyers sourcing research-use-only material — it is not a discussion of human use, and it is not legal advice.

Why chain length changes what you have to verify

LL-37 is the C-terminal fragment of human cathelicidin hCAP-18, a long, highly cationic, amphipathic sequence that research literature discusses in the context of innate immune signaling. For a buyer, the interesting fact is not the biology but the chemistry of making it. Peptides of this length are built residue by residue on solid phase, and no coupling cycle runs at perfect efficiency. Every additional cycle is another chance for a deletion sequence, a truncation, incomplete deprotection, or a side-chain modification to enter the crude mixture. A short tripeptide forgives a mediocre synthesis run. A 37-residue chain does not.

Cationic, amphipathic sequences add a second complication: they tend to aggregate and to adsorb onto surfaces, which makes both the purification and the analysis harder than for a simple short peptide. The practical consequence for a wholesale buyer is that cost per milligram is higher, purification is more demanding, and the commercial temptation to release a lot that only approximately meets specification is correspondingly stronger. That is precisely why documentation discipline matters more here than it does on a simple catalog item.

There is also a reason no single test is sufficient. Closely related impurities — a chain missing one residue, for instance — are still peptides, still absorb at the low ultraviolet wavelengths used for detection, and can elute very close to the target under a shallow gradient. HPLC answers the question of how much of what is in the vial is the main chromatographic peak. Mass spectrometry answers a completely different question: whether that main peak is the molecule the label claims. Buying on one number, without the other, leaves half the question open.

The analytical panel worth insisting on

The table below is the shortlist a sourcing conversation should cover. Not every supplier will run all of it on every lot, and not every research application needs all of it — but you should know which of these exist for the lot you are buying, and which do not.

Treat the list as questions rather than as a scorecard. A supplier that can explain which panels it runs, which it outsources, and why it draws the line where it does is giving you more useful information than one that simply asserts a high number.

Reading the documentation, not just the percentage

A certificate of analysis is a record of a specific test, on a specific lot, on a specific date. Anything that lacks those three anchors is marketing collateral wearing a lab coat. When a COA arrives, check that the lot number on the document matches the lot number on the vial in front of you, and that the date of analysis is consistent with the production date rather than predating it or floating years behind.

From there, look at the method detail. A credible HPLC report names the column chemistry, the mobile phase and gradient, the detection wavelength, and the run time, and it includes the chromatogram image with visible integration — not a cropped screenshot of a single number. You want to see the baseline, the shoulder peaks, and how the integration was drawn, because that is where a borderline lot gives itself away. A credible mass spectrometry report shows the spectrum and states the observed mass against the theoretical mass, rather than asserting that identity was 'confirmed' with nothing to inspect.

Several patterns in this industry should slow a buyer down. A certificate with no lot number. A purity claim with no chromatogram behind it. A document that is byte-for-byte identical across three different lots, which is not how analytical testing works. A supplier that treats the COA as a paid add-on or releases it only after payment clears — a business that charges for its own quality evidence has told you how it ranks that evidence. And pricing that will not resolve into a written tier structure until you have already committed. Publicly verifiable certificates invert all of this: the results are posted where a prospective partner can inspect them before any money moves, which is the arrangement Real Peptides operates under.

Diligence questions before a first wholesale order

Testing is one input into a sourcing decision; continuity is the other. Research programs and resale catalogs both depend on the second lot behaving like the first, so ask process questions alongside analytical ones.

Ask who performs the testing — in-house lab, contract lab, or a mix — and whether third-party verification is available on request. Ask whether retained samples are held from each lot, and for how long, because a retain is what makes an after-the-fact investigation possible at all. Ask what the supplier does when a lot falls out of specification: quarantine and reject, or quietly release with a revised number. Ask how material is stored and shipped, and whether documentation travels with the shipment or has to be chased down afterwards.

On the commercial side, ask for the tier structure in writing, including how tiers are determined and what happens to pricing on reorder. Ask what the minimum order looks like across categories rather than for a single headline compound. Ask where fulfillment originates and what the realistic dispatch window is, since a long or unpredictable lead time quietly becomes an inventory problem. Margin and minimum expectations vary widely by category, volume, and how you position the material, so be skeptical of any supplier that offers you a tidy profitability figure — a number that specific, offered that early, is usually a sales instrument rather than a fact.

Finally, ask about labeling. Research-use-only material should be labeled as such, consistently, on every unit, with no ambiguity about what the product is and is not. Suppliers that blur that line create a problem you inherit.

Where the licensing questions belong

This section is informational and is not legal advice. The regulatory picture around research compounds involves federal and state layers that interact differently depending on what kind of business you run, how you hold and transfer material, and how you describe it. Rather than accepting any supplier's summary of what you are permitted to do, treat these as questions for your own attorney and, where applicable, your state board.

Useful questions to put to counsel include: what business licensure or registration applies to a company in your category that stocks research-use-only material; what records and chain-of-custody documentation you should be keeping; how your labeling, marketing, and website language should be reviewed before publication; what restrictions apply to how you describe compounds to your own customers; and how the answers change if you operate across multiple states. Those questions have real answers, but they are jurisdiction-specific and change over time, which is exactly why a supplier is the wrong source for them. No vendor, including Real Peptides, can clear your compliance posture for you — that responsibility sits with your own counsel.

What Real Peptides does differently

Real Peptides supplies research-use-only compounds to businesses through its Wholesale Partner Program, and the quality position is specific rather than decorative. Every batch is tested to a 99%+ HPLC purity standard and runs through 7-panel batch testing, and the resulting certificates of analysis are published where a partner or prospective partner can verify them independently — before ordering, not after a dispute. That is the practical difference from suppliers that hold COAs behind a paywall or a support ticket: verification is the buyer's to perform, not a favor granted on request.

Fulfillment runs from within the United States with orders shipping in five to seven days, which makes reorder planning a calendar exercise rather than a guess. Pricing tiers are structured rather than negotiated ad hoc, and the wholesale application itself is a three-step process, so a qualified business can find out where it stands without an extended sales cycle. All catalog material is research use only and is not for human consumption.

Bringing this into a sourcing decision

If you are evaluating suppliers for long-chain research peptides and want to compare analytics rather than claims, start by pulling published certificates for the specific lots on offer and reading them against the panel above. Businesses that clear that bar and want to see tiered wholesale pricing can apply through the Real Peptides Wholesale Partner Program, where the application, the testing standard, and the published COAs are all available to review before any commitment is made.

For related sourcing reading, the same documentation standards apply across the catalog, including anti-inflammatory research compounds such as KPV Peptide 10mg and repair-signaling compounds like BPC-157 10mg, and buyers building a category can review the Gastrointestinal & Epithelial Research and Popular Peptides collections.